Skip to main content
U.S. flag

An official website of the United States government

The therapeutic potential of human umbilical cord blood derived mesenchymal stem cells in Alzheimer’s disease

Bibliographic

Year of Publication:
2010
Contact PI Name:
Hee Kyung Jin
Contact PI Affiliation:
College of Veterinary Medicine, Kyungpook National University, Daegu , South Korea
Co-Authors:
Hyun Ju Lee, Jong Kil Lee, Hyun Lee, Ji-woong Shin, Janet E. Carter, Toshiro Sakamoto, Hee Kyung Jin, Jae-sung Baea
Primary Reference (PubMED ID):
Funding Source:
Korean Ministry of Science and Technology (MoST)
Korean Ministry of Health and Welfare and Family Affairs
National Research Foundation of Korea (NRF)
Study Goal and Principal Findings:

The neuropathological hallmarks of Alzheimer’s disease (AD) include the presence of extracellular amyloid- peptide (Aβ) in the form of amyloid plaques in the brain parenchyma and neuronal loss. The mechanism associated with neuronal death by amyloid plaques is unclear but oxidative stress and glial activation has been implicated. Human umbilical cord blood-derived mesenchymal stem cells (hUCBMSCs) are being scrutinized as a potential therapeutic tool to prevent various neurodegenerative diseases including AD. However, the therapeutic impact of hUCB-MSCs in AD has not yet been reported. This study undertook in vitro work to examine the potential impact of hUCB-MSCs treatment on neuronal loss using a paradigm of cultured hippocampal neurons treated with Aβ. They confirmed that hUCB-MSCs co-culture reduced the hippocampal apoptosis induced by Aβ treatment. Moreover, in an acute AD mouse model to directly test the efficacy of hUCB-MSCs treatment on AD-related cognitive and neuropathological outcomes, they demonstrated that markers of glial activation, oxidative stress and apoptosis levels were decreased in AD mouse brain. Interestingly, hUCB-MSCs treated AD mice demonstrated cognitive rescue with restoration of learning/memory function. These data suggest that hUCB-MSCs warrant further investigation as a potential therapeutic agent in AD.  

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Biologic - Cell-based
Therapeutic Agent:
Human Umbilical Cord Blood Cells (HUCBC)
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
beta Amyloid Peptide Injection
Strain/Genetic Background:
C57BL/6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Histopathology
Activated Astrocytes
Activated Microglia
Immunochemistry
Oxidative Stress Markers
Glial Fibrillary Acidic Protein (GFAP)
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Caspase 3
Cell Biology
Apoptosis